

Andrew Cross

From: 340B Communications <340bcommunications@abbvie.com>

Sent: Wednesday, August 7, 2024 3:26 PM

To: Andrew Cross <Andrew.Cross@phvne.com>

Subject: RE: 340B Orphan Policy

Andrew,

Right now, there are no plans for to offer individual contracts.

While AbbVie has historically provided voluntary discounts to these entities, abuse of the 340B program has led us to reassess our 340B policies. We continue to support reforms to return the 340B program to its original intent.

It does extend to Botox – Allergan/AbbVie are one and the same. Please find the list of NDC's below. And, again, all non-orphan drugs remain available to those eligible entities.

NDC	Product Description
00023-9321	ALPHAGAN P 0.1% 5 ML DROPS
00023-9177	ALPHAGAN P 0.15% 10 ML EYE DROPS
00023-3921	BOTOX
00023-1145	BOTOX 100 UNIT VIAL
00023-3919	BOTOX COSMETIC
00023-9232	BOTOX COSMETIC 100 UNIT VIAL
00074-3012	DUOPA FILLED CASSETTE
00074-0817	HUMIRA 10MG/0.1ML PFS
00074-0067	HUMIRA 1X80MG,0.8ML; 1X40MG,0.4ML PFS 2 PK PED CROHN'S STARTER PACK
00074-0616	HUMIRA 20MG/0.2ML PFS
00074-0554	HUMIRA 40MG/0.4ML PEN
00074-2540	HUMIRA 80MG, 0.8ML PFS 3 PK PED CROHN'S STARTER PACK
00074-0124	HUMIRA 80MG,0.8ML 3 PENS
00074-4339	HUMIRA CROHNS PEN
00074-1539	HUMIRA KIT 80MG/0.8ML, 40MG/0.4ML 3 PENS
00074-0243	HUMIRA PFS 40MG/0.4ML PFS
00074-3799	HUMIRA PREFIL SYR
00074-2282	LUPRON 11.25 PED
00074-2440	LUPRON 15MG PED
00074-3641	LUPRON 3.75MG GYN
00074-3663	LUPRON 3MO 11.25 GYN
00074-3346	LUPRON 3MO 22.5MG URO
00074-9694	LUPRON 3-MTH PED
00074-3779	LUPRON 3-MTH PED
00074-3683	LUPRON 4MO 30MG URO
00074-3473	LUPRON 6MO 45MG URO
00074-3575	LUPRON DEPOT 6M PED
00074-3642	LUPRON 7.5 DEPOT URO
00074-2108	LUPRON 7.5MG PED
00074-2625	MAVYRET 100MG/40MG, 84 TABS
00074-2600	MAVYRET 50MG/20MG 1X28 SACHET
00074-3399	NORVIR ORAL POWDER 100MG
11980-0779	OCUFLOX .3% SOLUTION 10 ML

00023-3348	OZURDEX 0.7 MG IMPLANT
00074-2306	RINVOQ 15MG 30 DAY BOTTLE
00074-2310	RINVOQ 30MG 30 DAY BOTTLE
00074-2320	RINVOQ LQ 180ML ORAL SOLUTPION 1MG/ML
00074-1043	RINVOQ 45MG 28 DAY TABS BOTTLE
00074-1066	SKYRIZI INJECT 180MG/1.2ML(INNER PACK)**
00074-1069	SKYRIZI INJECT 360MG/2.4ML(INNER PACK)**
00074-2100	SKYRIZI INJECTION 150mg/mL PEN
00074-1050	SKYRIZI INJECTION 150mg/mL SYRINGE
00074-1065	SKYRIZI INJECTION 180MG/1.2ML OBI
00074-1070	SKYRIZI INJECTION 360MG/2.4ML OBI
00074-5015	SKYRIZI INJECTION 600MG/10ML SINGLE DOSE VIAL
00074-1040	SURVANTA
00074-0576	VENCLEXTA 100MG
00074-0561	VENCLEXTA 10MG
00074-0566	VENCLEXTA 50MG
00074-0579	VENCLEXTA STARTING PACK, 4X7 DAY WALLET
00074-4637	ZEMPLAR 2MCG/1MLV
00074-1658	ZEMPLAR 2ML FLPTP
00074-9036	ZEMPLAR ORAL 1MCG 30 CAPS
00074-9037	ZEMPLAR ORAL 2MCG 30 CAPS

Thank you.

Dave

DAVID KNIPPENBERG

Pricing Manager, PMP
ASP, 340B, and BFSF
US Commercial Operations

abbvie

Dept 0303

1 North Waukegan Road
North Chicago, IL 60045-6145

OFFICE +1 762-215-0447

EMAIL david.knippenberg@abbvie.com

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Andrew Cross <Andrew.Cross@phvne.com>

Sent: Wednesday, August 7, 2024 4:19 PM

To: 340B Communications <340bcommunications@abbvie.com>

Subject: [EXTERNAL] RE: 340B Orphan Policy

Hello,

This is disappointing news for our hospitals and their communities. Is there any chance to have them contract individually for some of these items at a 340B-like discount?

Also, does this extend to the Allergan NDCs such as Botox? If you have an updated list of all impacted NDCs, could you send that so we can get these excluded properly in our TPA's?

Thank you,
Andrew

From: 340B Communications <340bcommunications@abbvie.com>
Sent: Wednesday, August 7, 2024 3:07 PM
To: Andrew Cross <Andrew.Cross@phvne.com>
Subject: RE: 340B Orphan Policy

Good afternoon, Andrew.

That is correct. Effective August 1, 2024, AbbVie no longer offers voluntary 340B pricing on any of its orphan-designated drugs to the four covered entity types subject to the 340B orphan drug exclusion = Rural Referral Centers, Sole Community Hospitals, Critical Access Hospitals, and Free-standing Cancer Hospitals. However, all non-orphan drugs remain available to those eligible entities.

Thanks

Dave

DAVID KNIPPENBERG
Pricing Manager, PMP
ASP, 340B, and BFSF
US Commercial Operations



Dept 0303
1 North Waukegan Road
North Chicago, IL 60045-6145
OFFICE +1 762-215-0447
EMAIL david.knippenberg@abbvie.com

abbvie.com

This communication may contain information that is proprietary, confidential, or exempt from disclosure. If you are not the intended recipient, please note that any other dissemination, distribution, use or copying of this communication is strictly prohibited. Anyone who receives this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.

From: Andrew Cross <Andrew.Cross@phvne.com>
Sent: Wednesday, August 7, 2024 12:06 PM
To: 340B Communications <340bcommunications@abbvie.com>
Subject: [EXTERNAL] RE: 340B Orphan Policy

Hello,

I'm am seeing some hospital's receive a communication that this policy has ended 8/1/24. Can you confirm if that's correct?

Andrew

Andrew Cross

Manager, 340B

Prairie Health Ventures • phvne.com

575 Fallbrook Blvd. • Suite 204 • Lincoln, NE 68521

p. [402.742.2211](tel:402.742.2211) • c. [952-836-7818](tel:952-836-7818) • Andrew.Cross@phvne.com